Lightpoint Medical raises £5.8m Series C funding from Oxford Technology Management and others to scale commercial operations.

Lightpoint Medical has secured £5.8m in a Series C financing round to support the commercial rollout of its robotic cancer detection probe. The investment saw participation from the British Business Bank Future Fund, alongside existing backers including Oxford Technology, Venture Founders, and Coutts Bank. The fresh capital will fund expanded clinical trials and early commercialisation of the company's SENSEI device.

The raise follows recent regulatory approvals for the robotic probe in Europe, the United States, and Australia. Lightpoint has already established distribution partnerships in several markets and plans to widen its international reach over the coming months as clinical studies continue across multiple cancer types.